ZYBERNO
Stock Report
Updated Sep 1, 2026

Zhengye Biotechnology Holding Limited (ZYBT)

Healthcare • NASDAQ

$1.73

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
Zhengye Biotechnology Holding Limited (ZYBT) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.03x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-16.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Zhengye Biotechnology Holding Limited (ZYBT) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.73
Market Cap:$81.92M

Valuation Multiples (3)

P/B Ratio:1.87x
P/S Ratio:4.92x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$85.39M
Pfcf Ratio:41.27x

Price Action & Momentum (1)

% of 52-Week High:13.2%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:47.0%
Fundamental Growth Rate (g):-7.5%

Margin Analysis (1)

Ebitda Margin:-42.4%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:3.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.14x
Quick Ratio:0.82x
Cash Ratio:0.42x

Leverage Analysis (3)

Debt To Equity Ttm:0.03x
Debt-to-Equity Ratio:0.03x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-20.75x
Times Interest Earned:-20.75

Capital Structure (4)

Working Capital:2,420,000.00
Cash And Cash Equivalents:7,197,000.00
Long Term Debt:$1.37M
Net Debt:$3.48M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$16.64M
Cost Of Revenue Ttm:$13.23M

Profitability Breakdown (2)

$3.41M-$10.08M

Bottom Line Performance (3)

-$9.98M
Income Before Tax:-$10.28M
Ebitda Ttm:-7,049,000.00

Operating Expenses (5)

Operating Expenses:13,496,000.00
R And D Expense:2,576,000.00
Sga Expense:4,434,000.00
Income Tax Expense:$1.59M
Interest Expense:486,000.00

Expense Ratios (3)

R And D To Revenue Percentage:15.5%
Sga To Revenue Percentage:26.6%
Ebitda Margin:-42.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$62.41M
Current Assets:$19.65M
Ppe Net:33,863,000.00
Goodwill:0.00
Intangible Assets:$6.73M

Liability Structure (4)

Total Liabilities:18,558,000.00
Current Liabilities:17,230,000.00
Long Term Debt:$1.37M
Short Term Debt:$9.31M

Equity & Capital (3)

Equity:$43.85M
Retained Earnings:-$3.10M
Common Stock:2,000,000,000.00

Working Capital Items (3)

Accounts Receivable:2,643,000.00
Inventory:5,601,000.00
Accounts Payable:6,296,000.00

Special Items (2)

Contract Liabilities:498,000.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

$1.91M$1.77M

Investment Activities (1)

Investing Cash Flow:-$1.81M

Financing Activities (3)

Financing Cash Flow:$4.62M
Dividends Paid Ttm:2,195,000.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$10.08M
Long Term Debt Repayments:$11.81M

Non-Cash Items (1)

Depreciation Amortization Ttm:3,035,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.21

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.35
Operating Cash Flow Per Share:$0.04

Book Value & Capital (2)

Book Value Per Share:$0.93
Cash Per Share:0.15

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.27x
Working Capital Turnover Ttm:6.88x

Receivables Management (2)

Receivables Turnover Ttm:6.30x
Days Sales Outstanding Ttm:57.98

Inventory Management (2)

Inventory Turnover Ttm:2.36x
Days Inventory Outstanding Ttm:154.56

Payables & Cash Cycle (2)

Days Payable Outstanding:173.74
Cash Conversion Cycle:38.80
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:50.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:47.0%
Fundamental Growth Rate (g):-7.5%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:ZYBT
Company Name:Zhengye Biotechnology Holding Limited
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:47.35M
Shares Outstanding Basic:47.35M
Shares Outstanding Diluted:47.35M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 04:47:00 UTC
Data Timestamp:2026-08-20T14:06:22.872079
Scroll to Top